

Table 2. Expression of ARPP protein in SMA's

Case No.	Histology	Age	Sex	Positive rates	Intensities of immunoreactivity
1	SMA1	1 year	M	+	++
2	SMA1	3 months	M	+	+
3	SMA1	3 months	F	++	++
4	SMA1	4 months	F	++	++
5	SMA2	2 years	F	+++	+
6	SMA2	2 years	F	+++	+
7	SMA2	3 years	F	+++	+
8	SMA3	6 years	M	++	+
9	SMA3	14 years	F	+++	+
10	SMA3	52 years	M	+++	+
11	SMA3	10 years	F	+	+

Positive rates were classified based on the proportions of the positive fibers: +++ =>90%; ++ = 90-50%; + = 50-5%; - = 5-0%. Intensities of immunoreactivity were classified into three groups: +++ = strong; ++ = weak; ± = borderline (not shown).

ly low (cases 8 and 10 in table 1), indicating that the checkerboard-like pattern had been lost in these cases.

Congenital Fiber Type Disproportion. All 3 specimens expressed ARPP (cases 11-13 in table 1). In 1 patient (case 11), almost all the myofibers showed diffuse ARPP expression, but in the other 2 (cases 12 and 13), ARPP-positive and negative myofibers were admixed (fig. 2G and H). In the latter 2 patients, large and small fibers were admixed, and ARPP was preferentially expressed in the small myofibers (fig. 2G and H).

ARPP Is Induced in Hypertrophic Myofibers of SMA's

To evaluate ARPP expression in SMA patients, 11 skeletal muscle tissue biopsy specimens from SMA patients were subjected to immunohistochemical analysis. ARPP was expressed in all 11 samples (table 2). In patients with SMA1, in which muscle atrophy is severe, and those with SMA2, in which muscle atrophy is less severe than that associated with SMA1, we found that the ARPP-positive and negative fibers were arranged in groups, respectively. All the grouped ARPP-positive myofibers expressed ARPP uniformly (fig. 2I and J). In 2 of the patients with SMA3, in which muscle atrophy is milder than that associated with SMA1 and SMA2 [12-14], the ARPP-positive myofibers were arranged in a checkerboard-like pattern similar to that of normal muscle (fig. 2K and L), but in the other 2, the ARPP-positive myofibers were arranged in groups (fig. 3D1). Double-labeled immunohistochemistry of samples from patients with SMA1 and SMA2 with the α -ARPP(FL) and α -slow-MHC Abs revealed that the ARPP-positive myofibers did

not necessarily coincide with the slow-MHC-positive myofibers (fig. 3C1-3). As shown in figure 3C1-3, there were ARPP-positive hypertrophic and ARPP-negative atrophic myofibers among the slow-MHC-positive myofibers, whereas, in the SMA3 patients, the ARPP- and slow-MHC-positive myofibers coincided (fig. 3D1-3).

Discussion

MD is a genetically inherited muscle disease characterized histopathologically by the presence of necrosis and concurrent regeneration of myofibers, resulting in progressive destruction of myofibers [12, 14-18]. DMD is the most common subtype of MD and is believed to occur due to lack of the DMD gene product, dystrophin. BMD, LGMD and FSHMD have a later onset, are less severe clinically and progress more slowly than DMD [15]. In this study, we found that ARPP expression was apparently down-regulated in patients with every subtype of MD. However, in patients with congenital myopathies, ARPP expression was not down-regulated in atrophic myofibers but tended to be up-regulated in atrophic or damaged myofibers. This result suggests that such a down-regulation of ARPP may be a phenomenon specific to MDs but not to other muscle diseases. However, the down-regulation of ARPP might be due to reduced numbers of type I myofibers in patients with MDs. Therefore, we subjected muscle samples from patients with MDs to immunohistochemical analysis to detect expression of slow fiber-specific MHC, fast fiber-specific MHC and embryonic fiber-

specific MHC and found that slow- and fast-MHC-positive myofibers were arranged in a checkerboard-like pattern similar to that of normal muscle [Nakada et al., unpubl. observation]. Furthermore, embryonic MHC expression was restricted to regenerating myofibers [Nakada et al., unpubl. observation]. Thus, it is evident that ARPP expression was significantly down-regulated in slow-MHC-positive type 1 myofibers. It remains to be determined why ARPP was down-regulated in patients with MDs. Furthermore, an interesting question to be resolved is whether down-regulation of ARPP in muscles of MD patients could be useful for monitoring the clinical status of the disease. Further studies with larger numbers of patients are required to explore these possibilities.

The congenital myopathies are a heterogeneous group of disorders each of which is characterized by marked structural abnormalities [13]. In this study, we found that ARPP expression was induced in the skeletal muscles of patients with congenital myopathies. Both the numbers of ARPP-positive myofibers and their ARPP expression levels in the muscle tissue were apparently increased in comparison with those in normal muscle. The mechanisms responsible for the induction of ARPP expression in patients with congenital myopathies are not known at this stage. It has been reported that type 1 fibers predominate in patients with congenital myopathies, including nemaline myopathy, central core disease, CFTD and myotubular myopathy [14, 19]. In view of our previous finding that ARPP is selectively expressed in type 1 myofibers, we suggest that ARPP expression in patients with congenital myopathies might be associated with the type of myofiber. Indeed, we found that ARPP-positive myofibers co-expressed slow MHC (fig. 3B1–3), which supports this idea. Type 1 fibers have cytochemical features that indicate a mainly aerobic-oxidative metabolic profile, whereas type 2B fibers are mainly endowed with an anaerobic-glycolytic metabolic machinery [20]. Thus, it is an interesting speculation that metabolic disorder may occur in these diseased muscles and that altered expression of ARPP in congenital myopathies may be involved in their pathogenesis. Further studies are required to address this hypothesis. Furthermore, in patients with nemaline myopathy, we found that ARPP-positive fibers corresponded well to nemaline-rod-containing fibers, which led us to speculate that ARPP expression might be associated with nemaline rod formation, although the pathogenesis of these rods is still unknown.

SMA is an inherited denervating muscle disease, in which the anterior horn motor neurons of the spinal cord are affected, resulting in neurogenic muscle atrophy [13,

14, 21, 22]. Clinically, SMAs have been subclassified into three subtypes: SMA1, or Werdnig-Hoffmann disease, with an onset during infancy and a poor clinical prognosis; SMA2, the intermediate type with a later onset in the first year of life and longer survival without respiratory failure during infancy, and SMA3, or Kugelberg-Welander disease, with an onset in late childhood and considerable clinical heterogeneity [13, 14, 21, 22]. In this study, we found that, in patients with SMAs, ARPP-positive myofibers tended to be distributed in groups. In all those with SMA1 and 2, which are categorized as severe and intermediate subtypes, respectively, the ARPP-positive myofibers were arranged in groups. In half of the patients with SMA3, which is categorized as a milder subtype, the ARPP-positive myofibers were arranged in groups but, in the other half, the ARPP-positive and negative fibers were arranged in a checkerboard-like pattern similar to that of normal muscle. As the grouped myofibers were reported to result from the process of denervation, innervation and subsequent denervation of re-innervated myofibers [12], we suggest that the grouped arrangement of ARPP-positive myofibers in SMA patients may also result from denervation of the motor units. Furthermore, the ARPP expression levels were higher in patients with severe disease than in those with mild disease, which suggests that ARPP expression in SMA patients is associated with disease severity. If this proves to be the case, evaluation of ARPP in denervated muscle may be useful for monitoring the status of this disease. Further studies on larger numbers of patients are required to explore this possibility.

References

- 1 Moriyama M, Tsukamoto Y, Fujiwara M, Kondo G, Nakada C, Baba T, Ishiguro N, Miyazaki A, Nakamura K, Hori N, Sato K, Shomori K, Takeuchi K, Satoh H, Mori S, Ito H: Identification of a novel human ankyrin-repeated protein homologous to CARP. *Biochem Biophys Res Commun* 2001;285:715-723.
- 2 Tsukamoto Y, Senda T, Nakano T, Nakada C, Hida T, Ishiguro N, Kondo G, Baba T, Sato K, Osaki M, Mori S, Ito H, Moriyama M: Arpp, a new homolog of Carp, is preferentially expressed in type I skeletal muscle fibers and is markedly induced by denervation. *Lab Invest* 2002;82:645-655.
- 3 Kemp TJ, Sadusky TJ, Saltisi F, Carey N, Moss J, Yang SY, Sassoon DA, Goldspink G, Coulton GR: Identification of Ankrd2, a novel skeletal muscle gene coding for a stretch-responsive ankyrin-repeat protein. *Genomics* 2000;66:229-241.
- 4 Pallavicini A, Kojic S, Bean C, Vainzof M, Salamon M, Ievolella C, Bortoletto G, Pacchioni B, Zatz M, Lanfranchi G, Faulkner G, Valle G: Characterization of human skeletal muscle Ankrd2. *Biochem Biophys Res Commun* 2001;285:378-386.
- 5 Zou Y, Evans S, Chen J, Kuo H-C, Harvey RP, Chien KR: CARP, a cardiac ankyrin repeat protein, is downstream in the *Nkx2-5* homeobox gene pathway. *Development* 1997;124:793-804.
- 6 Ikeda K, Emoto N, Matsuo M, Yokoyama M: Molecular identification and characterization of a novel nuclear protein, whose expression is upregulated in insulin resistant animals. *J Biol Chem* 2003;278:3514-3520.
- 7 Chu W, Burns DK, Swerlick RA, Presky DH: Identification and characterization of a novel cytokine-inducible nuclear protein from human endothelial cells. *J Biol Chem* 1995;270:10236-10245.
- 8 Baumeister A, Arber S, Caroni P: Accumulation of muscle ankyrin repeat protein transcript reveals local activation of primary myotube end compartments during muscle morphogenesis. *J Cell Biol* 1997;139:1231-1242.
- 9 Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, Lyons GE, Kedes L: A novel cardiac-restricted target for doxorubicin: CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. *J Biol Chem* 1997;272:22800-22808.
- 10 Ishiguro N, Baba T, Ishida T, Takeuchi K, Osaki M, Araki N, Okada E, Takahashi S, Saito M, Watanabe M, Nakada C, Tsukamoto Y, Sato K, Ito K, Fukayama M, Mori S, Ito H, Moriyama M: Carp, a cardiac ankyrin-repeated protein, and its new homologue, Arpp, are differentially expressed in heart, skeletal muscle, and rhabdomyosarcomas. *Am J Pathol* 2002;160:1767-1778.
- 11 Miyazaki A, Tsukamoto Y, Sato K, Ohgi S, Moriyama M: Genomic organization of the human *Arpp* gene. *Yonago Acta Med* 2002;45:1-8.
- 12 Heffner RR Jr, Schochet SS Jr: Skeletal muscle; in Damjanov I, Linder J (eds): *Anderson's Pathology*, ed 10. St Louis, Mosby, 1996, pp 2653-2690.
- 13 Sewry CA, Dubowitz V: Histochemistry and immunocytochemistry of muscle in health and disease; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 251-282.
- 14 Nonaka I: *Muscle Pathology for Physicians* (in Japanese). Tokyo, Nihon-iji-shinposha, 1999, pp 2-75.
- 15 Hoffman EP: Dystrophinopathies; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 385-432.
- 16 Kaplan J-C, Beckmann JS, Fardeau M: Limb girdle muscular dystrophies; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 433-463.
- 17 Tawil R, Griggs RC: Facioscapulohumeral dystrophy; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 464-470.
- 18 Voit T: Congenital muscular dystrophies; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 503-524.
- 19 Goebel HH: Congenital myopathies; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 525-540.
- 20 Carpenter S, Karpati G (eds): *Pathology of Skeletal Muscle*, ed 2. New York, Oxford University Press, 2001, pp 41-50.
- 21 Carpenter S: Muscle pathology on semithin resin sections; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 283-295.
- 22 Bushby K: Genetic counselling in muscle disease; in Karpati G, Hilton-Jones D, Griggs RC (eds): *Disorders of Voluntary Muscle*, ed 7. Cambridge, Cambridge University Press, 2001, pp 705-738.

Clinical Report

Girl With Monosomy 1p36 and Angelman Syndrome due to Unbalanced der(1) Transmission of a Maternal Translocation t(1;15)(p36.3;q13.1)

Hiroyuki Torisu,^{1*} Toshiyuki Yamamoto,^{2,3} Takehisa Fujiwaki,⁴ Mitsutaka Kadota,⁵ Mitsuo Oshimura,⁵ Kenji Kurosawa,³ Shinjiro Akaboshi,¹ and Akira Oka¹

¹Division of Child Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, Japan

²Gene Research Center, Tottori University, Yonago, Japan

³Division of Medical Genetics, Kanagawa Children's Medical Center (KCMC), Yokohama, Japan

⁴Department of Pediatrics, Matsue Red Cross Hospital, Matsue, Japan

⁵Department of Genetics and Cell Technology, School of Life Sciences, Faculty of Medicine, Tottori University, Yonago, Japan

We report on a girl with monosomy 1p36.3 and Angelman syndrome due to an unbalanced transmission of a maternal balanced chromosomal translocation. She manifested monosomy 1p36 and Angelman syndrome including generalized hypopigmentation, ataxic movements, intractable seizures with characteristic electroencephalographic (EEG) abnormality compatible with Angelman syndrome, and other minor anomalies, large anterior fontanelle, severe psychomotor retardation, and seizures due to monosomy 1p36. Her karyotype was 45, XX, der(1) t(1;15)(p36.31;q13.1), -15, derived from maternal translocation. Molecular analysis determined a breakpoint of 1p between D1S243 and D1S468, which suggested that most genes contributing to the common phenotype are in the distal region.

© 2004 Wiley-Liss, Inc.

KEY WORDS: Angelman syndrome; chromosomal abnormality; chromosome 1; monosomy 1p36

INTRODUCTION

Recently, we studied a girl with partial monosomy 1p36.3 and 15q13 derived from a maternal balanced translocation. Some of her manifestations were compatible with Angelman syndrome, due to deletion of a maternal allele on 15q [Angelman, 1965]. She also showed manifestations not seen in patients with Angelman syndrome due to haploinsufficiency of the 1p36 region.

In recent years, subtelomeric rearrangements have been identified as a major cause of mental retardation and/or malformation syndromes [de Vries et al., 2003]. With the advance of molecular and cytogenetic methods, a specific phenotype of partial monosomy 1p36 has been characterized by moderate to severe psychomotor retardation, seizures, growth delay, and minor anomalies [Keppler-Noreuil et al., 1995; Reish et al., 1995; Giraudeau et al., 1997; Shapira et al., 1997;

Fan et al., 1999; Riegel et al., 1999; Slavotinek et al., 1999; Wu et al., 1999; Knight-Jones et al., 2000; Giraudeau et al., 2001; Angle et al., 2002; Okamoto et al., 2002; Heilstedt et al., 2003]. A phenotype/genotype study showed that this condition is a contiguous gene syndrome and that most genes contributing to the phenotype might be in the distal region of 1p36 [Shapira et al., 1997; Slavotinek et al., 1999; Wu et al., 1999; Knight-Jones et al., 2000; Heilstedt et al., 2003].

CLINICAL REPORT

A female infant (Fig. 1) was referred for seizures at the age of 7 months. She was the first child of a healthy non-consanguineous 34-year-old mother and a 28-year-old father. Her mother did not have any history of abortions or gestational difficulties.



Fig. 1. The patient at age of 14 months.

*Correspondence to: Hiroyuki Torisu, M.D., Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

E-mail: htorys@pediatr.med.kyushu-u.ac.jp

Received 2 September 2003; Accepted 9 December 2003

DOI 10.1002/ajmg.a.30413

Published online 21 September 2004 in Wiley InterScience (www.interscience.wiley.com)

She was delivered spontaneously at 41 weeks of gestation, weighing 2,738 g. Before her first epileptic attack comprising a series of tonic spasms, she attained almost complete head control by the age of 3 months. However, after this event, she showed deterioration, and electroencephalographic (EEG) abnormalities were noted.

On admission, she weighed 7.55 kg (-0.41 SD), was 66.5 cm (-0.19 SD) in length, and had a 42 cm (-0.67 SD) head circumference. Her hands and feet were small, the palmar and plantar lengths being 7.3 cm (-5.0 SD) and 7.8 cm (-3.7 SD), respectively. She had an unusual facial appearance with frontal bossing, hypertelorism, a flat nasal root, a pointed chin, apparently low-set ears with asymmetry and cupping, and a preauricular tag on right side. Generalized hypopigmentation of the skin, hair, and irises was noted. There were no anomalies of eyes, fundi, external genitalia, or limbs.

She had severe psychomotor developmental delay, postural hypotonia with head lag, and did not smile or pay any attention to her surroundings. Cranial nerve function was normal, but she had ataxic movements of the upper limbs, like an intentional tremor, especially when she brought her hands to her mouth. Her seizures consisted of infrequent generalized tonic spasms and frequent atypical absences. These clinical findings are summarized in Table I.

Results of laboratory examinations including urinalysis, complete blood count, total protein, urea nitrogen, liver enzyme, serum electrolyte, creatine kinase, uric acid, and total cholesterol levels were showed normal. Metabolic screening including blood gas analysis, ammonia, lactate, and pyruvate in blood and cerebrospinal fluid, and an amino acid

profile in blood and urine, also showed normal results. No anomaly of heart and other visceral organs was documented by ultrasonographic examination. She had a large anterior fontanelle. Brain magnetic resonance imaging (MRI) disclosed mild cerebral atrophy with thin corpus callosum and large cortical sulci. Her interictal EEG findings consisted of continuous generalized 1-2 Hz, over 300 µV, and theta waves with frequent spikes in the occipital areas during sleep.

High-resolution chromosome study of her peripheral lymphocytes documented a karyotype 45, XX, der(1) t(1;15)(p36.31;q13.1), -15 (Fig. 2A). Deletion of the critical region for Angelman syndrome was also confirmed by fluorescence in situ hybridization (FISH) (Fig. 2B). Her mother had the balanced translocation 46, XX, t(1;15)(p36.31;q13.1), and her father had normal chromosomes.

After admission, a tube feeding was required because of inadequate oral intake. Although the seizures ceased with 200 mg/day of valproate and 0.9 mg/day of clonazepam, she did not catch up in development and had severe psychomotor retardation.

MOLECULAR INVESTIGATIONS

After informed consent, we investigated the breakpoints of chromosomes 1 and 15 by molecular methodology. Genomic DNAs from peripheral blood lymphocytes of the patient and her parents were obtained, and then analyzed by PCR amplification of polymorphic microsatellite markers located on the 1p36 region (D1S207, D1S214, D1S243, D1S244, D1S450, D1S468, D1S2633, D1S2660, D1S2667, D1S2736,

TABLE I. Manifestations in Our Patient and Those With Angelman Syndrome (Deletion Type) and Monosomy 1p36 Syndrome

Findings	Angelman syndrome [Smith et al., 1996]		Our case	1p36 deletion syndrome [Shapira et al., 1997]	
	n	%		n	%
Minor anomalies					
Large/wide mouth/large chin	24/26	92	-		
Minor anomalies at birth	0/27		+		
Pointed chin			+	12/15	80
Flat nasal bridge			+	11/17	65
Low-set ear(s)			+	10/17	59
Ear asymmetry			+	8/14	57
Deep-set eyes			-	7/14	50
Physical abnormalities					
Microcephaly	8/15	53	-	5/13	38
Growth delay	21/26	81	-	11/13	85
Hypopigmentated	19/26	73	+		
Large anterior fontanelle			+	11/11	100
Fifth finger short/clinodactyly			+	9/14	64
Small hands/feet			+	3/15	20
Congenital heart defect			-	3/18	17
Neurological abnormalities					
Severe mental retardation	27/27	100	+	12/13	92
Motor delay/hypotonia	15/22	68	+	12/13	92
Seizures	26/27	96	+	13/18	72
Ataxic movements	27/27	100	+		
Sleeping problems	18/21	86	+		
Eye/vision problems			-	9/12	75
Hearing deficits			-	5/9	56
Happy disposition in infancy	21/22	95	-		
Paroxysmal laughter	21/23	91	-		
Abusive behavior			-	5/9	56
Examination					
Abnormal EEG	25/25	100	+	8/14	57
CT/MRI anomaly			+	2/11	18
Infantile cardiomyopathy			-	4/9	44




Fig. 2. A: Partial karyotype obtained from a phytohemagglutinin blood culture using trypsin (GTG) banding and schematic demonstration. The arrow indicates chromosome 15, which is translocated to the short arm of chromosome 1. The karyotype is 45,XX,der(1)t(1;15)(p36.31;q13.1),-15. B: Photograph of FISH. We used a red probe (D15S10: 15q11.2), for the region responsible for Angelman syndrome; and a green probe (D15Z1: 15p11.2) and another red probe (PML: 15q22) as control. The arrow indicates the normal chromosome 15, in which all of the probes were identified. "der(1)" indicates the derivative chromosome, in which the PML probe could be identified, whereas the red probe responsible for Angelman syndrome could not be identified. FISH utilizing a DNA probe confirmed the deletion of 15q13. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]




Fig. 3. Schematic presentation of the deleted regions of chromosome 1 and 15. The determination of the deleted region was based solely on the presence or absence of the parental alleles. The areas with black and white indicate the identified deleted region and non-deleted region, respectively. The gray area is that which we could not identify as deleted or not. ND, not deleted; -, not informative. Italic characters indicate the existence of well-known genes responsible for Angelman syndrome.

D1S2845, and D1S2870) and the 15q11-13 region (D15S11, D15S128, D15S122, D15S113, D15S97, and D15S165), according to methods described elsewhere [Yamamoto et al., 2001]. The primer sequences of the markers were obtained from the Genome Data Base (<http://www.genethon.fr>).

On chromosome 1, the breakpoint was determined to be between D1S243 and D1S468, because we could not identify the maternal allele of D1S243 in the patient. In the same way, the breakpoint on chromosome 15 was determined to be between D15S113 and D15S165 (Fig. 3).

DISCUSSION

The breakpoints of the chromosomes were confirmed to be in the telomeric region from 1p36.3 and the centromeric region from 15q13. The deleted region in chromosome 15 includes small nuclear ribonucleoprotein-associated polypeptide N (*SNPRN*) and the ubiquitin protein ligase E3A gene (*UBE3A*) which was major gene causing Angelman syndrome (Fig. 3) [Kishino et al., 1997; Matsuura et al., 1997]. We could not determine whether the deleted region includes the genes between D15S113 and D15S165, such as the gamma-aminobutyric acid A receptor, beta 3 gene (*GABRB3*), and the oculocutaneous albinism II gene (*OCA2*), which could associate with intractable epilepsy and hypopigmentation. However, the deleted region probably includes the two genes, because, as for deletion type of Angelman syndrome, there is one common breakpoint cluster at distal end, which is distal to the characteristic genes [Kuwano et al., 1992], and because specific findings in our patient are mostly compatible with Angelman syndrome [Buoni et al., 1999].

She had a distinct facial appearance with marked floppiness and a profound mental deficit, which appeared to be exceptionally severe for Angelman syndrome. Thus, these findings were probably due to partial monosomy 1p36. So far, over 50 patients with partial monosomy 1p36 have been reported and it is thought to be more common than other deletion syndromes [Keppler-Noreuil et al., 1995; Reish et al., 1995; Giraudeau et al., 1997; Shapira et al., 1997; Fan et al., 1999; Riegel et al., 1999; Slavotinek et al., 1999; Wu et al., 1999; Knight-Jones et al., 2000; Giraudeau et al., 2001; Angle et al., 2002; Okamoto et al., 2002; de Vries et al., 2003; Heilstedt et al., 2003]. Partial monosomy 1p36 is a contiguous gene deletion syndrome comprising, hypotonia, developmental delay (usually severe), and growth abnormalities (growth retardation, microcephaly, and obesity), craniofacial anomalies with large anterior fontanelle, prominent forehead, deep-set eyes, flat nasal bridge, midface hypoplasia, ear asymmetry, a pointed chin, and orofacial clefting. Our patient had almost all of these findings (Table I).

In comparison with previously reported patients, the deleted region in our patient is limited to only the terminal region of 1p and its size is one of the smallest [Keppler-Noreuil et al., 1995; Reish et al., 1995; Giraudeau et al., 1997; Shapira et al., 1997; Fan et al., 1999; Riegel et al., 1999; Slavotinek et al., 1999; Wu et al., 1999; Knight-Jones et al., 2000; Heilstedt et al., 2003]. A previous genotype/phenotype study showed that most genes contributing to the common phenotype are in the distal region [Shapira et al., 1997; Slavotinek et al., 1999; Wu et al., 1999; Knight-Jones et al., 2000]. The study of our patient supported this notion, suggesting that there is a critical region for this syndrome between D1S468 and pter [Wu et al., 1999; Heilstedt et al., 2003].

The potassium voltage-gated channel, shaker-related subfamily, beta member 2 gene, *KCNAB2*, is located in 1p36, and deletion of this gene may be responsible for the seizures in patients with monosomy 1p36 syndrome [Heilstedt et al., 2001]. Our patient had a severe seizure phenotype including infantile spasms, although the *KCNAB2* locus was not deleted,

which resides proximal to the not-deleted microsatellite marker D1S468.

The gamma-aminobutyric acid A receptor, delta gene (*GABRD*) is another gene assigned to the 1p36 region [Emberger et al., 2000; Windpassinger et al., 2002]. This gene has been reported to represent an integral mechanism for the functioning of the central nervous system, and a locus for the action of many mood- and emotion-altering agents. Although further investigation is required to elucidate whether this gene is included in the deleted region or not, *GABRD* may be involved in the psychomotor developmental delay in patients with partial monosomy 1p36.

REFERENCES

- Angelman H. 1965. 'Puppet' children: A report of three cases. *Dev Med Child Neurol* 7:681-688.
- Angle B, Yen F, Hersh JH, Gowans G, Barch M. 2002. Partial duplication 4q and deletion 1p36 in monozygotic twins with discordant phenotypes. *Am J Med Genet* 111:307-312.
- Buoni S, Grosso S, Pucci L, Fois A. 1999. Diagnosis of Angelman syndrome: Clinical and EEG criteria. *Brain Dev* 21:296-302.
- de Vries BB, Winter R, Schinzel A, van Ravenswaaij-Arts C. 2003. Telomeres: A diagnosis at the end of the chromosomes. *J Med Genet* 40:385-398.
- Emberger W, Windpassinger C, Petek E, Kroisel PM, Wanger K. 2000. Assignment of the human GABAA receptor delta-subunit gene (*GABRD*) to chromosome band 1p36.3 distal to marker NIB1364 by radiation hybrid mapping. *Cytogenet Cell Genet* 89:281-282.
- Fan YS, Jung J, Hamilton B. 1999. Small terminal deletion of 1p and duplication of 1q: Cytogenetics, FISH studies, and clinical observations at newborn and at age 16 years. *Am J Med Genet* 86:118-123.
- Giraudeau F, Aubert D, Young I, Horsley S, Knight S, Kearney L, Vergnaud G, Flint J. 1997. Molecular cytogenetic detection of a deletion of 1p36.3. *J Med Genet* 34:314-317.
- Giraudeau F, Taine L, Biancalana V, Delobel B, Journel H, Missirian C, Lacombe D, Bonneau D, Parent P, Aubert D, Hauck Y, Croquette MF, Toutain A, Mattei MG, Loiseau HA, David A, Vergnaud G. 2001. Use of a set of highly polymorphic minisatellite probes for the identification of cryptic 1p36.3 deletions in a large collection of patients with idiopathic mental retardation. *J Med Genet* 38:121-125.
- Heilstedt HA, Burgess DL, Anderson AE, Chedrawi A, Tharp B, Lee O, Kashork CD, Starkey DE, Wu YQ, Noebels JL, Shaffer LG, Shapira SK. 2001. Loss of the potassium channel beta-subunit gene, *KCNAB2*, is associated with epilepsy in patients with 1p36 deletion syndrome. *Epilepsia* 42:1103-1111.
- Heilstedt HA, Ballif BC, Howard LA, Lewis RA, Stal S, Kashork CD, Bacino CA, Shapira SK, Shaffer LG. 2003. Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome. *Am J Hum Genet* 72:1200-1212.
- Keppler-Noreuil KM, Carroll AJ, Finley WH, Rutledge SL. 1995. Chromosome 1p terminal deletion: Report of new findings and confirmation of two characteristic phenotypes. *J Med Genet* 32:619-622.
- Kishino T, Lalonde M, Wagstaff J. 1997. *UBE3A/E6-AP* mutations cause Angelman syndrome. *Nat Genet* 15:70-73.
- Knight-Jones E, Knight S, Haussler H, Regan R, Flint J, Martin K. 2000. Neurodevelopmental profile of a new dysmorphic syndrome associated with submicroscopic partial deletion of 1p36.3. *Dev Med Child Neurol* 42:201-206.
- Kuwano A, Mutirangura A, Dittrich B, Buiting K, Horsthemke B, Saitoh S, Niikawa N, Ledbetter SA, Greenberg F, Chinault AC, et al. 1992. Molecular dissection of the Prader-Willi/Angelman syndrome region (15q11-13) by YAC cloning and FISH analysis. *Hum Mol Genet* 1:417-425.
- Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, Rommens JM, Beaudet AL. 1997. De novo truncating mutations in *E6-AP* ubiquitin-protein ligase gene (*UBE3A*) in Angelman syndrome. *Nat Genet* 15:74-77.
- Okamoto N, Toribe Y, Nakajima T, Okinaga T, Kurosawa K, Nonaka I, Shimokawa O, Matsumoto N. 2002. A girl with 1p36 deletion syndrome and congenital fiber type disproportion myopathy. *J Hum Genet* 47:556-559.

- Reish O, Berry SA, Hirsch B. 1995. Partial monosomy of chromosome 1p36.3: Characterization of the critical region and delineation of a syndrome. *Am J Med Genet* 59:467-475.
- Riegel M, Castellan C, Balmer D, Brecevic L, Schinzel A. 1999. Terminal deletion, del(1)(36.3), detected through screening for terminal deletions in patients with unclassified malformation syndromes. *Am J Med Genet* 82:249-253.
- Shapira SK, McCaskill C, Northrup H, Spikes AS, Elder FF, Sutton VR, Korenberg JR, Greenberg F, Shaffer LG. 1997. Chromosome 1p36 deletions: The clinical phenotype and molecular characterization of a common newly delineated syndrome. *Am J Hum Genet* 61:642-650.
- Slavotinek A, Shaffer LG, Shapira SK. 1999. Monosomy 1p36. *J Med Genet* 36:657-663.
- Smith A, Wiles C, Haan E, McGill J, Wallace G, Dixon J, Selby R, Colley A, Marks R, Trent RJ. 1996. Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion. *J Med Genet* 33:107-112.
- Windpassinger C, Kroisel PM, Wagner K, Petek E. 2002. The human γ -aminobutyric acid A receptor delta (*GABRD*) gene: Molecular characterisation and tissue-specific expression. *Gene* 292:25-31.
- Wu YQ, Heilstedt HA, Bedell JA, May KM, Starkey DE, McPherson JD, Shapira SK, Shaffer LG. 1999. Molecular refinement of the 1p36 deletion syndrome reveals size diversity and a preponderance of maternally derived deletions. *Hum Mol Genet* 8:313-321.
- Yamamoto T, Akaboshi S, Ninomiya H, Nanba E. 2001. DEFECT 11 syndrome associated with agenesis of the corpus callosum. *J Med Genet* 38:E5.

Genetics

A non-NF2 case of schwannomas of vestibular and trigeminal nerves with different genetic alterations of NF2 gene: case report

Atsushi Kambe, MD^{a,*}, Hideki Kamitani, MD, PhD^a, Takashi Watanabe, MD, PhD^a, Akira Oka, MD, PhD^b, Hirotaka Inagaki, MD, PhD^c, Takashi Ishii, MD, PhD^c, Keisuke Ueki, MD, PhD^d

^aDivision of Neurosurgery, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago 683-8504 Japan

^bDivision of Neuropediatrics, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, 683-8504 Japan

^cDepartment of Neurosurgery, Tottori Prefectural Central Hospital, Tottori, 680-0901 Japan

^dDepartment of Neurosurgery, Dokkyo University School of Medicine, Tochigi, 321-0293 Japan

Received 26 November 2003; accepted 29 March 2004

Abstract

Background: We report a patient with 2 separate schwannomas, a vestibular schwannoma and a trigeminal schwannoma, that were attached to each other and appeared to be a single tumor on imaging studies.

Case Description: The patient, without any family history of neurofibromatosis, presented with a progressive hearing loss and mild left facial nerve palsy. Magnetic resonance imaging showed a snowman-like tumor in the left cerebellopontine angle. Surgical exposure revealed that the tumor consisted of 2 “kissing” schwannomas, a trigeminal and vestibular schwannoma. Molecular genetic analysis detected a 1-base pair deletion at exon 10 of the neurofibromatosis type 2 (NF2) gene in the trigeminal schwannoma, but not in the acoustic schwannoma. However, loss of heterozygosity at chromosome 22q (D22S282 and D22S929) was detected in both tumors, losing the same allele.

Conclusion: Multiple schwannomas in non-NF2 patients are extremely rare, and possible causes include simple coincidence or germline genetic alteration of adjacent gene on chromosome 22q, similar to the cause recently suggested in familial schwannomatosis. Although not always possible, molecular genetic examination may help to understand the underlying mechanism and would be warranted in such cases.

© 2005 Elsevier Inc. All rights reserved.

Keywords:

Trigeminal schwannoma; Vestibular schwannoma; NF2 gene; Mutations

1. Introduction

Intracranial schwannomas account for approximately 8% of intracranial tumors [4,5,7] and most frequently arise from the vestibular nerve followed by the trigeminal nerve. However, it is rare to find 2 independent schwannomas simultaneously in the same patient, unless the patient is affected by neurofibromatosis type 2 (NF2), an autosomal dominant disorder caused by a germline mutation of the NF2 gene. Here we report a patient with 2 simultaneous

schwannomas, in which we performed molecular genetic analysis to investigate the possible cause.

2. Case report

A 46-year-old man without any family history of neurofibromatosis noticed partial hearing loss (70 dB) and mild left facial nerve palsy (House and Brackmann grade 2). There was no trigeminal dysfunction. Magnetic resonance imaging (MRI) of the brain demonstrated a heterogeneous mass with a size of 2.0 × 1.5 × 1.8 cm, showing a snowman-like configuration. The tumor mass was enhanced homogeneously by gadolinium except the cystic compo-

* Corresponding author. Tel.: +81 859 34 8036; fax: +81 859 34 8082.

E-mail address: kanimo@grape.med.tottori-u.ac.jp (A. Kambe).




Fig. 1. Preoperative gadolinium-enhanced axial MRI. Left, Preoperative gadolinium-enhanced axial MRI demonstrating the caudal portion of the mass showing extension into the left auditory canal. Right, Preoperative gadolinium-enhanced axial MRI demonstrating the rostral portion, with cystic components involving the left trigeminal nerve.

ment. On close examination, the posterior portion of the mass showed extension into the left internal auditory canal, whereas the anterior portion with cystic components apparently involved the left trigeminal nerve (Fig. 1). He had no history of previous radiation to any part of the body.

The patient underwent a left retromastoid suboccipital craniotomy. The tumor initially looked like a single mass despite the presence of constricted portion. After internal decompression of the caudal part of the tumor, however, it was found that the rostral and caudal masses were separate tumors that only weakly adhered to each other. The caudal tumor occupying the left internal auditory canal had a typical schwannoma appearance, and the rostral tumor

arising from the trigeminal nerve had both solid and cystic components. Therefore, this patient was considered to have 2 separate schwannomas, a vestibular and a trigeminal schwannoma. Both tumors including the portion extending into the left internal auditory canal were totally removed.

The patient recovered well after surgery but showed complete loss of hearing in the left ear and mild left trigeminal dysesthesia. The patient did not have any stigmata of neurofibromatosis such as cutaneous neurofibromas, café au lait spots, or posterior subcapsular cataracts. MRI performed 2 months after the surgery showed no residual tumor. Histologic examination showed that both tumors were typical schwannomas without any




Fig. 2. Molecular genetic analysis on the trigeminal tumor (T1) and the acoustic tumor (T2) in comparison with the blood DNA (N). There was 1-base pair deletion in the NF2 exon 10 in T1, but not in T2 nor in the blood DNA (left). On the other hand, LOH at chromosome 22q12 (D22S282 and D22S929) was evident in both tumors, apparently losing the same allele.

histologic atypia. Molecular genetic analysis of the tumors was performed to investigate the possible influence of the NF2 gene alteration on the formation of the schwannomas.

After obtaining written informed consent, DNA was extracted from each tumor and from peripheral blood lymphocytes of the patient. All 17 exons of the NF2 gene were polymerase chain reaction-amplified from the tumor DNA samples using the previously reported primers and were directly sequenced [6]. In addition, loss of heterozygosity (LOH) analysis of the NF2 locus chromosome 22q12 was performed on 3 microsatellite markers, D22S929, D22S282, and D22S1163, using the constitutional DNA as a reference. There was 1-base pair deletion at exon 10 causing a frame shift in the trigeminal schwannoma, but there was no mutation either in the acoustic schwannoma or in the constitutional DNA (Fig. 2). On the other hand, the microsatellite analysis showed that both tumors had LOH at chromosome 22q (D22S282 and D22S929) (Fig. 2). The pattern of allelic loss indicated that the same allele was lost in both tumors.

3. Discussion

Most intracranial schwannomas present with a solitary lesion, and bilateral occurrence of vestibular schwannomas by itself fulfills the clinical diagnostic criteria for NF2. Furthermore, simultaneous growth of multiple schwannomas in different loci usually indicates high likelihood of NF2 as well. Without underlying NF2, combination of unilateral vestibular and trigeminal schwannomas is a quite rare condition, with only 2 similar cases reported in the literature. Both cases were considered to be forme fruste of NF2 by the authors, although no molecular genetic analysis was performed [1,7].

In the present case, molecular genetic analysis provided interesting information. Although both tumors had loss of 1 allele of chromosome 22q around the NF2 lesion, only 1 had detectable mutation in the NF2 gene, and the other had no detectable NF2 gene alteration. Given that no germline NF2 mutation was detected in the blood lymphocytes while the trigeminal schwannoma had a NF2 mutation, it was unlikely that this patient was affected by NF2. If the patient suffered mosaic type of NF2, the same mutation should have been detected in the vestibular schwannoma as well [2]. Instead, there are other possibilities that would explain the mechanism of the present case. First, the formation of 2 tumors in this patient was a mere coincidence, although it would be an extremely remote possibility considering the incidence of sporadic schwannoma. Second, this patient may have the similar molecular genetic background found in familial schwannomatosis. In a recent study, MacCollin et al demonstrated that most of the tumors found in patients with familial schwannomatosis showed LOH at chromosome 22q and many, but not all, of those also showed typical truncation mutation of the

NF2 gene. Based on the data, they proposed that the responsible gene or locus for the schwannomatosis should lie centromeric to NF2, and inherited mutation of this gene/locus contributes to the tumor formation in combination with somatic inactivation of NF2 [3]. In the present case, the molecular genetic event detected is consistent with this mechanism, although other currently unknown mechanisms are not excluded. Existence of vestibular schwannoma automatically excludes our case from clinical definition of schwannomatosis, but the phenomenon itself appears to be very much similar.

Although the present patient apparently does not have NF2, currently available methods or knowledge does not allow us to tell definitely whether this patient has the risk of schwannomatosis-like situation. But, again, considering that the mere coincidence of 2 sporadic tumors could be an extremely remote possibility, it would be safe to monitor patients closely by imaging studies for new tumor formation, when a similar situation is encountered.

Acknowledgment

We thank Mrs Kumiko Iwanaga for processing the photographs.

References

- [1] Kasuya H, Kadowaki H, Yato S, Kubo O, Kagawa M, Kitamura K. Forme fruste of von Recklinghausen's disease: unilateral association of an orbital neurofibroma, a trigeminal neurinoma, and an acoustic neurinoma, case report. *Neurosurgery* 1986;18:208-11.
- [2] Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. *J Med Genet* 2003;40:109-14.
- [3] MacCollin M, Willett C, Heinrich B, Jacoby LB, Acierno Jr JS, Perry A, Louis DN. Familial schwannomatosis: exclusion of the NF2 locus as the germline event. *Neurology* 2003;60:1968-74.
- [4] Okada Y, Shima T, Nishida M, Okita S. Large sixth neuroma involving the preoptine region, case report. *Neurosurgery* 1997;40:608-10.
- [5] Russell DS, Rubinstein LJ. Tumours of the nerve roots and peripheral tumours of the neurone [2 chapters]. *Pathology of tumours of the nervous system*, 4th ed. London: Edward Arnold; 1977. p. 372-436.
- [6] Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of Merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningioma. *Cancer Research* 1999;59:5995-8.
- [7] Vaquero J, Cabezudo JM, Leunda G, Carrillo R, Bravo G. Simultaneous posterior and middle cranial fossa neurinomas. *Acta Neurochirurgica (Wien)* 1981;55:321-7.

Original article

Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS

Masato Mori*, Takanori Yamagata, Tamako Goto, Shigeiko Saito, Mariko Y. Momoi

Department of Pediatrics, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Tochigi 329-0498, Japan

Received 16 September 2003; received in revised form 26 December 2003; accepted 26 December 2003

Abstract

The long-term effects of the sodium salt of dichloroacetic acid (DCA) were evaluated in four patients with mitochondrial encephalomyelopathy with lactic acidosis and stroke-like episodes (MELAS) carrying A3243G mutation. Oral administration of DCA in MELAS patients was followed for an average of 5 years 4 months. Serum levels of lactate and pyruvate were maintained at around 10 and 0.6 mg/dl, respectively. Serum levels of DCA were 40–136 µg/ml. Symptoms responding to treatment included persistent headache, abdominal pain, muscle weakness, and stroke-like episodes. In contrast, no improvements in mental status, deafness, short stature, or neuroelectrophysiological findings were observed. Adverse effects included mild liver dysfunction in all patients, hypocalcemia in three and peripheral neuropathy in one. None of these adverse events was severe enough to require discontinuation of treatment. To determine suitable indications for DCA therapy, analysis of many more patients who have undergone DCA administration is required.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Mitochondrial encephalomyelopathy with lactic acidosis and stroke-like episodes; Treatment; Dichloroacetate; Long-term effects

1. Introduction

Mitochondrial diseases remain largely untreatable, despite numerous advances in our understanding of molecular genetics and pathology. Mitochondrial encephalomyelopathy with lactic acidosis and stroke-like episodes (MELAS) represents one of the most common mitochondrial disorders of childhood. The disease presents as a slowly progressive entity associated with deteriorating neuromuscular function. Patients suffer from a wide variety of symptoms, including intractable abdominal pain, headache, stroke-like episodes, dementia, deafness, muscle weakness, and short stature [1]. Among these, stroke-like episodes play an important part in the neurological prognosis of MELAS. Affected patients suffer worsened mental and motor function or visual disturbance, depending upon the severity and location of brain lesions. About 80% of MELAS patients display a point mutation in the tRNA-Leu (UUR) gene of mitochondrial DNA [2].

In contrast to the molecular genetics, relatively little progress has been reported in treatment regimens for these

conditions. Intravenous administration of cytochrome *c*, or oral administration of CoQ10 with or without vitamin supplementation reportedly shows some clinical effect in MELAS patients [3–8]. These reagents are thought to act as substrates, electron carriers in the respiratory chain, or antioxidants. The sodium salt of dichloroacetic acid (DCA) is effective in reducing circulating lactate by increasing pyruvate dehydrogenase activity, but has been trialed in the treatment of congenital lactic acidosis and Leigh syndrome without obvious clinical success [9–15]. DCA has been widely used and studied for its beneficial effect in the improvement of lactic acidosis and in the metabolism of ischemic tissues [16–20]. Despite numerous studies examining DCA administration in animals and humans, the effects in mitochondrial disorders remain controversial [21]. We have previously reported on the short-term results of DCA administration in three MELAS patients in 1998, with all three patients exhibiting beneficial effects directly related to the treatment [22]. To assess the long-term effects of DCA administration in patients with mitochondrial disorders, we report herein on four MELAS patients treated with DCA for up to 5 years. We discuss the application of DCA therapy in patients with mitochondrial disorders, including adverse effects.

* Corresponding author. Tel.: +81-285-58-7366; fax: +81-285-44-6123.
E-mail address: morim@jichi.ac.jp (M. Mori).

Table 1
Clinical findings and laboratory data before and after treatment with DCA

	Patient 1			Patient 2			Patient 3			Patient 4		
	Before	After 1 year	After 6 years	Before	After 1 year	After 5 years	Before	After 1 year	After 5 years	Before	After 1 year	After 4 years
Headache	Everyday	1–2/month	None	Everyday	1–2/week	3/month	1/week	0–1/month	None	1/week	0–1/month	None
Stroke-like episodes	1–3/year	None	None	–	–	+	1/month	None	None	1/month	None	+
Seizure	1–2/month	1–2/year	None	–	–	–	1–2/month	1–2/week	1–2/week	1–2/month	1–2/year	1–2/year
Weakness	–	–	–	+++	++	+	+	+	+	+	+	+
Hearing loss	+	+	+	–	–	–	+	–	–	+	+	+
Intelligence	5years	5years	5 years	IQ 97	IQ 98	IQ 101	6 years	7 years	7 years	IQ 58	IQ 46	IQ < 40
EEG	3 months	9 months	3 months	IQ 97	IQ 98	IQ 101	8 months	11 months	10 months	IQ 58	IQ 46	IQ < 40
	Spikes at Rt T	No change	No change	Spike and waves	No change	No change	Spikes at Lt O	No change	Spike and waves	Spikes at Rt O	No change	Spike and waves
ABR (threshold) (dB)	65	65	75–85	Normal	Normal	Elongation of latency	65	25	25	35–45	ND	ND
Cranial CT calcification/low density area	+ /Rt O	No change	ND	– /–	No change	ND	+ /Lt O	No change	No change	+ /Rt O	No change	No change
Liver dysfunction	ND	+	+	ND	+	+	ND	+	+	ND	+	+
Abdominal echography	ND	Hypertrophy of liver/polyps of gallbladder	Hypertrophy of liver/polyps of gallbladder	ND	Hypertrophy of liver	NP	ND	Hypertrophy of liver	Polyps of gallbladder	ND	Hypertrophy of liver	Hypertrophy of liver
NCV	ND	Normal	Normal	ND	Normal	Normal	ND	Decreased at Sural N.	No change	ND	ND	ND

–, not detected; +, detected, able to walk more than 1 km; ++, unable to walk more than 1 km; + + +, unable to walk more than 100 m; Rt, right; Lt, left; T, temporal area; O, occipital area; ND, not done; NP, nothing in particular; EEG, electroencephalography; ABR, auditory brainstem responses; NCV, nerve conduction velocity. Intelligence, patients 1 and 3 undertook the Kaufmann Assessment Battery for Children. Patients 2 and 4 undertook the Wechsler Intelligence Scale for Children-III.

2. Cases

Four patients with MELAS were enrolled in the DCA treatment program. All four MELAS patients displayed the A3243G mutation. Clinical course for three of the four MELAS patients has been reported elsewhere [22]. Additional data from a 9-year-old female patient who joined the program at a later date are included. She displayed mental retardation, short stature and mild hearing disturbance, and had been treated with DCA since an episode of intractable status epilepticus 4 years previously. All four patients with MELAS were female. Ages of patients 1–4 at the start of treatment were 16 years 11 months, 9 years 5 months, 13 years 11 months and 9 years 2 months, respectively. Duration of treatment ranged from 4 years 2 months to 6 years 1 month. The major clinical features of patients are listed in Table 1.

3. Treatment program

The ethics committee of Jichi Medical School approved the DCA treatment program for patients with mitochondrial encephalomyopathy. Informed consent was obtained from patients when possible, or from their parents. DCA is a prime class reagent manufactured by Tokyo Kasei Co., Ltd (Tokyo, Japan). Patients were initially given three separate oral 50 mg/kg doses of DCA at 12-h intervals, followed by 25 mg/kg doses twice a day. DCA administration was supplemented with 100 mg/day of vitamin B1. Doses were adjusted relative to serum and CSF levels of lactate and pyruvate. Serum lactate levels were maintained between 10 and 20 mg/dl to prevent depletion of serum lactate.

Laboratory studies included routine blood and urine tests, electroencephalography, auditory brain stem responses, abdominal and cardiac ultrasonography, and neuroimaging. The Kaufmann Assessment Battery for Children (K-ABC) or Wechsler Intelligence Scale for Children III (WISC-III) was used to assess mental function.

4. Results

Clinical and laboratory findings of MELAS patients before and after treatment are listed in Table 1. Persistent headache was observed in all four patients, with complete resolution in three cases and partial improvement in the other case after DCA treatment. Stroke-like episodes were documented in three patients before treatment. Two patients experienced stroke-like episodes during the treatment period. Lactate and pyruvate levels in CSF were higher than those in serum. DCA doses were increased following these episodes, with no subsequent attacks. Epileptic seizures were controllable in three of the patients. Patient 2 displayed epileptic seizure during the treatment period, at which time serum lactate levels were around 30 mg/dl.

Due to mild liver dysfunction, carbamazepine was initiated instead of increasing dose of DCA. Improvements in muscle weakness were observed in patient 2, who was unable to walk 1 km before treatment due to weakness and fatigability, but over the course of treatment became capable of walking as far as she wanted. Effect on hearing acuity varied, but was partial, if evident at all.

Mental tests revealed no worsening of dementia in two patients, decreased scores in one, and normal intelligence in one. No changes were observed on electroencephalography. Auditory brain stem response studies in three patients revealed elevated threshold and prolonged latencies. Absent nerve potential was detected in the sural nerve in one patient who developed weakness and paresthesia of the lower limbs after 5 months of treatment. Symptoms in the lower limbs did not change during the remainder of the 5-year treatment period. No prominent changes were apparent on neuroimaging. Serum lactate levels were maintained at around 10 mg/dl (Fig. 1a), and pyruvate at around 0.6 mg/dl (Fig. 1b). Levels of lactate and pyruvate in CSF ranged from 25 to 42, and from 0.8 to 1.4 mg/dl, respectively (Fig. 2a and b).

Dosage of DCA was adjusted according to the clinical condition of patients and serum levels of lactate (Fig. 3). A daily dose of around 30 mg/kg appeared to represent the optimal dose for obtaining stable and constant amelioration of symptoms.

With regard to possible adverse effects, serum transaminases were slightly elevated, although not in a progressive




Fig. 1. Time course for levels of (a) serum lactate and (b) pyruvate. After DCA treatment was started, serum lactate and pyruvate levels were maintained within almost normal ranges.




Fig. 2. Time course for cerebrospinal fluid levels of (a) lactate and (b) pyruvate. After DCA treatment was started, cerebrospinal fluid levels of lactate and pyruvate decreased immediately. However, levels remained higher than serum levels.

manner in all patients (Fig. 4). Abdominal ultrasonography revealed enlargement of the liver in all patients. This was improved by changing anticonvulsant in one patient. No space-occupying lesions were detected in the livers. Polyp-like echogenicity was detected in the gallbladders of patients 1 and 3, but no progression was seen. Since development of polyps in patient 3 obviously occurred during treatment, DCA administration may have been responsible. Three patients developed asymptomatic hypocalcemia during treatment. Levels normalized in one patient, but vitamin D supplementation was required in the other two. Peripheral neuropathy presented as weakness




Fig. 3. Dosage of DCA. All patients were treated with about 30 mg/kg per day of DCA.




Fig. 4. Time course of transaminase (ALT). Transaminase levels were increased from 6 to 12 months after initiation of DCA treatment. No patients elected to discontinue treatment.

of the lower limbs and drop foot in patient 3. These symptoms remained stable for 3 years.

5. Discussion

Although our knowledge about the genetic mutations and molecular pathologies of mitochondrial disorders is steadily increasing, these conditions remain largely untreatable. Therapeutic drug regimens have included cytochrome *c*, CoQ10, DCA, and vitamins B1, B2, and B6. CoQ10 is reportedly effective for suppressing major symptoms in CoQ10-deficient patients through its function as an antioxidant and electron carrier in the respiratory chain. However, the efficacy of these drugs for other diseases remains controversial [23]. Nakagawa and associates [24] reported that 22 months of co-administrating cytochrome *c* and vitamins B1 and B2 to a patient with Kearns-Sayre syndrome somewhat improved extraocular symptoms, but had no effect on ocular symptoms. The same group reported a 1-year follow-up of cytochrome *c* treatment in nine patients, including four patients with MELAS [3]. Weakness, fatigability, respiratory failure, and nystagmus were resolved, but no improvements in laboratory findings were observed.

DCA is a pyruvate dehydrogenase activator, and has been used to ameliorate lactic acidosis caused by either overproduction or underutilization of lactic acid [21]. So far, the effects of DCA have been described in treatments for shock, sepsis, hypoxia [16,17], diabetes mellitus [18], myocardial ischemia [19], and mitochondrial disorders [9–15,25,26], in both human and animal models. The beneficial effects of DCA are thought to be attributable to either increased oxidative phosphorylation or increased ATP utilization by tissues. If the effects occur through enhancement of respiratory chain activity, then such effects should be limited in mitochondrial disorders in which the respiratory chain is partially affected. Cells or tissues must maintain a certain level of respiratory chain activity in order

to be able accept the enhanced pyruvate dehydrogenase complex (PDHC) product. In addition, serum lactate levels need to be maintained so that substrate can be supplied. Based on data taken from the 4-year average levels seen in MELAS patients, serum lactate levels of around 10 mg/dl may be appropriate.

Our results from four MELAS patients after 4–6 years of treatment showed that DCA is effective in suppressing symptoms of a recurring nature. Headache, abdominal pain and stroke-like episodes appear to be ameliorated by DCA, while persistent symptoms such as dementia, deafness, or short stature are unaffected. Chandy and associates reported that DCA decreased the size of infarcts in a primate model of focal cerebral ischemia. They reported that size of the infarct was reduced to one-third by prior administration of DCA [27]. Their report on the animal model of cerebral ischemia is consistent with the effects we observed for complete suppression of stroke-like episodes by DCA. Taniguchi and associates [28] reported that the effect of DCA on hypoxic heart function was due to increasing efficiency of ATP use by cardiac tissue, and not through an increase in the efficiency of ATP production. We cannot confirm that this is what happened in the tissues of our patients or what was the cause of differences seen in responsiveness to DCA. Several possible factors may define responsiveness to DCA. Remnant activity of the respiratory chain in cells, tissues, or organs should represent the central factor defining responsiveness. Tissue dependence on glycolysis could be another factor.

Mild liver dysfunction was observed in all patients with MELAS. Since hepatocarcinogenicity of DCA has been reported in rodents [29,30], these patients were followed by ultrasonographic studies of the liver. No patients developed abnormal echogenicity in the livers. Walgren and associates [31] reported that humans might not be susceptible to DCA-induced hepatocarcinogenesis, as DCA does not increase DNA synthesis in cultured human hepatocytes. Enlargement of the liver observed in three patients was possibly due to glycogen accumulation, as has been documented in rodent livers [32]. Peripheral neuropathy observed in one patient may be part of the symptoms of mitochondrial disorders, or may represent an adverse effect of DCA administration. The ineffectiveness of vitamin B supplementation in neuropathy seems to support the former. Hypocalcemia observed in three patients was asymptomatic and improved with administration of vitamin D.

DCA treatment was administered for MELAS in four patients, all of whom obtained improved daily quality-of-life (QOL) without experiencing further severe stroke-like episode. However, two patients with lactate levels in CSF exceeding those in serum experienced stroke-like episodes. The mitochondrial heteroplasmy of tissues must be considered when treating patients. No one proposed cessation of treatment, despite the adverse effects described above. To make DCA treatment valid and safe, several problems remain to be solved. Firstly, better protocols for determining

optimal dose of DCA for each patient are required. In the present cases, dose was regulated by carefully observing patient condition and serum and CSF lactate levels. However, that was insufficient to avoid overdoses, as required lactate levels differ for each patient. Secondly, whether DCA improves QOL for each patient must be documented. With these considerations in mind, symptoms that do not respond to treatment must be carefully followed for many years, as further degradation could lead to the patient becoming bed-ridden. Thirdly, hepatocarcinogenesis and other potential serious adverse effects of DCA need to be carefully monitored throughout the lifetime of the patient. The high incidences of hypocalcemia and liver dysfunction also require investigation. Further studies with animal models may help to provide answers to these questions.

Acknowledgements

The authors would like to thank Drs Y. Kuroda and M. Ito (Tokushima University) for measuring DCA concentrations.

Supported in part by a Research Grant (14B-4) for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan.

References

- [1] Pavlakis SG, Rowland LP, DeVivo DL, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a distinctive clinical syndrome associated with ragged-red fibers. *Ann Neurol* 1984;16:481–8.
- [2] Goto Y, Nonaka I, Horai S. A mutation in the tRNA^{Leu} (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. *Nature* 1990;348:651–3.
- [3] Tanaka J, Nagai T, Arai H, Inui K, Yamanouchi H, Goto Y, et al. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. *Brain Dev* 1997;19:262–7.
- [4] Kuroda Y, Ito M, Naito E, Yokota I, Matsuda J, Saijo T, et al. Concomitant administration of sodium dichloroacetate and vitamin B1 for lactic acidemia in children with MELAS syndrome. *J Pediatr* 1997;131:450–2.
- [5] Yamamoto M, Sato T, Anno M, Ujike H, Takemoto M. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with recurrent abdominal symptoms and coenzyme Q10 administration. *J Neurol Neurosurg Psychiatry* 1987;50:1475–81.
- [6] Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T. Mitochondrial encephalopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. *J Neurol Sci* 1989;90:263–71.
- [7] Chen RS, Huang CC, Chu NC. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. *Eur Neurol* 1997;37:212–8.
- [8] Abe K, Matsuo Y, Kadekawa J, Inoue S, Yanagihara T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. *J Neurol Sci* 1999;162:65–8.
- [9] Kuroda Y, Ito M, Toshima K, Takeda E, Naito E, Hwang TJ, et al. Treatment of chronic congenital lactic acidosis by oral administration of dichloroacetate. *J Inher Metab Dis* 1986;9:244–52.
- [10] Toth PP, El-Shanti H, Eivins S, Rheas WJ, Klein JM. Transient improvement of congenital lactic acidosis in a male infant with

- pyruvate decarboxylase deficiency treated with dichloroacetate. *J Pediatr* 1993;123:427–30.
- [11] Byrd DJ, Krohn HP, Winkler L, Steinborn C, Hadam M, Brodehl J, et al. Neonatal pyruvate dehydrogenase deficiency with lipoate responsive lactic acidemia and hyperammonaemia. *Eur J Pediatr* 1989;148:543–7.
- [12] Kimura S, Osaka H, Saitou K, Otsuki N, Kobayashi T, Nezu A. Improvement of lesions shown on MRI and CT scan by administration of dichloroacetate in patients with Leigh syndrome. *J Neurol Sci* 1995;134:103–7.
- [13] Cragen WJ. Leigh disease with deficiency of lipoamide dehydrogenase: treatment failure with dichloroacetate. *Pediatr Neurol* 1996;14:69–71.
- [14] Takanashi J, Sugita K, Tanabe Y, Maemoto T, Niimi H. Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation. *J Neurol Sci* 1997;145:83–6.
- [15] Kimura S, Otsuki N, Nezu A, Tanaka M, Takeshita S. Clinical and radiologic improvements in mitochondrial encephalomyopathy following sodium dichloroacetate therapy. *Brain Dev* 1997;19:535–40.
- [16] Stacpoole PW, Lorenz AC, Thomas RG, Harman EM. Dichloroacetate in the treatment of lactic acidosis. *Ann Intern Med* 1988;108:58–63.
- [17] Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. *N Engl J Med* 1992;327:1564–9.
- [18] Stacpoole PW, Greene YJ. Dichloroacetate. *Diabetes Care* 1992;15:785–91.
- [19] Bersin RM, Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. *Am Heart J* 1997;134:841–55.
- [20] Lewis JF, DaCosta M, Wargowich T, Stacpoole P. Effects of dichloroacetate in patients with congestive heart failure. *Clin Cardiol* 1998;21:888–92.
- [21] Stacpoole PW, Henderson GN, Yan Z, James MO. Clinical pharmacology and toxicology of dichloroacetate. *Environ Health Perspect* 1998;106(Suppl 4):989–94.
- [22] Saitoh S, Momoi MY, Yamagata T, Mori Y, Imai M. Effects of dichloroacetate in three patients with MELAS. *Neurology* 1998;50:531–4.
- [23] Przyrembel H. Therapy of mitochondrial disorders. *J Inher Metab Dis* 1987;10:129–46.
- [24] Nakagawa E, Osari S, Yamanouchi H, Matsuda H, Goto Y, Nonaka I. Long-term therapy with cytochrome c, flavin mononucleotide and thiamine diphosphate for a patient with Kearns-Sayre syndrome. *Brain Dev* 1996;18:68–70.
- [25] DeStefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. *Neurology* 1995;46:1586–90.
- [26] Saijo T, Naito E, Ito M, Takeda E, Hashimoto T, Kuroda Y. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. *Neuropediatrics* 1991;22:166–7.
- [27] Chandy MJ, Ravindra J. Effect of dichloroacetate on infarct size in a primate model of focal cerebral ischaemia. *Neurol India* 2000;48(3):227–30.
- [28] Taniguchi M, Wilson C, Hunter CA, Pehowich DJ, Clanachan AS, Lopaschuk GD. Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. *Am J Physiol Heart Circ Physiol* 2001;280(4):H1762–9.
- [29] DeAngelo AB, Daniel FB, Most BM, Olson GR. The carcinogenicity of dichloroacetic acid in the male Fischer 344 rat. *Toxicology* 1996;114:207–21.
- [30] Chen CW. Biologically based dose–response model for liver tumors induced by trichloroethylene. *Environ Health Perspect* 2000;108(Suppl 2):335–42.
- [31] Walgren JE, Kurtz DT, McMillan JM. The effect of the trichloroethylene metabolites trichloroacetate and dichloroacetate on peroxisome proliferation and DNA synthesis in cultured human hepatocytes. *Cell Biol Toxicol* 2000;16(4):257–73.
- [32] Kato-Weinstein J, Lingohr MK, Orner GA, Thrall BD, Bull RJ. Effects of dichloroacetate on glycogen metabolism in B6C3F1 mice. *Toxicology* 1998;130:141–54.

発達障害と遺伝 —最近の知見—

杉江陽子*1, *2, 杉江秀夫*2

はじめに

発達障害とは、遺伝要因も含めて発達期、特に早期に多くの因子が作用し脳の機能障害が起こり、それによって発達が損なわれた状態をいう。精神発達遅滞、言語発達障害、学習能力の特異的発達障害、運動機能発達障害、広汎性発達障害など非常に広範囲にわたっているが、ここでは自閉性障害(以下自閉症)を例に説明し、精神遅滞、言語発達障害、学習障害について簡単に述べた。注意欠陥/多動障害(精神医学的には行動障害に分類されるが)についても簡単に触れた。

遺伝について

一般に遺伝病とは、一つの遺伝子に異常(疾患原因遺伝子)があるために病気になってしまう単一遺伝子疾患をいうが、生活習慣病や癌などのように複数の遺伝子に変化(疾患感受性遺伝子)がありその上に環境因子が関わって発病する多因子疾患がある(図1)。今回の発達障害はいずれもその多くが多因子疾患と考えられている。多因子疾患では一つの遺伝子の変化だけで発病することなく、疾患感受性遺伝子の中で変化をもった遺伝子の数が多いほど発病の危険が増すと考えられている。病気が家系内に多く




図1 病気にかかわる遺伝因子と環境因子

*1 葵町こどもクリニック

*2 浜松市発達医療総合センター小児神経科

みられ、双子研究で一卵性双生児の一致率が二卵性一致率より高く、兄弟の罹患率が一般の罹患率より高いなどの特徴があり、これらが地域を越えて共通して認められると多因子疾患が疑

われる。これら多因子疾患の感受性遺伝子を見つけるためにどのようにして研究が進められているかを簡単に紹介する。なお、文中、図中でてくる略語は表1を参照とする。

表1 略語

VNTR	variable number of tandem repeat
SNP	single nucleotide polymorphism
AUTS1	a susceptibility gene locus for autism on chromosome 15q (7q?)
AUTS2	a susceptibility gene locus for autism on chromosome 7q
AUTS3	a susceptibility gene locus for autism on chromosome 3q
GABA	γ aminobutyric acid A
5-HTT	serotonin transporter
MKRN3/ZNF127	makorin ring finger protein 3
SNRPN	small nuclear ribonucleoprotein polypeptide N
UBE3A	ubiquitin protein ligase E3A
GABRB3	γ -aminobutyric acid A receptor β 3
GABRA5	γ -aminobutyric acid A receptor α 5
GABRG3	γ -aminobutyric acid A receptor γ 3
OCA2	oculo cutaneous albinism
HERC2	hect domain and RLD2
APBA2	amyloid β (A4) precursor protein-binding family A member 2
PTPN9	protein-tyrosine phosphatase nonreceptor-type 9
HOXA1	homeo box A1
RELN	reelin
IMMP2L	inner mitochondrial membrane peptidase 2-like
WNT2	wingless-type MMTV integration site family member 2
FOXP2	forkhead box P2
SPCH1	speech and language disorder 1
5-HT2AR	serotonin 2A receptor
MECP2	methyl CpG-binding protein
AGTR2	angiotensin II receptor
ARHGEF6	rho guanine nucleotide exchange factor 6
ARX	aristaless-related homeobox gene
FACL4	fatty acid-CoA ligase 4
FMR2	fragile-X mental retardation 2
GDII	guanine dissociation inhibitor 1
IL1RAP1	interleukin-1 receptor accessory proteinlike 1
OPHN1	oligophrenin 1
PAK3	p21-activated kinase
TM4SF2	transmembrane 3 superfamily member 2
VCX-A	variable charged
DYX2	dyslexia specific 2
DYX3	dyslexia specific 3
DAT1	dopamine transporter
DRD4	dopamine receptor D4

遺伝性疾患の研究の方法

大きく分けて2つの方法がある。候補遺伝子法とゲノムスクリーン法である。

候補遺伝子法は従来から行われている方法で、ある仮説のもとに可能性のありそうな遺伝子を選びその遺伝子について直接調べていく方法である。ある仮説とはその疾患の生物学的特徴や染色体異常合併例、単一遺伝子疾患に合併する例などこれまでの多くの報告を参考にして選択される。

最近の遺伝研究には目覚ましいものがあり、ヒトの染色体の地図が完成され、これで得られた情報をもとに研究方法が大規模かつ網羅的になってきている。ヒトには22組の常染色体と1組の性染色体があるが、ゲノムスクリーン法とはまず全部の染色体を見渡して、染色体のどの辺りにその病気を起こす遺伝子がありそうか検討をつける解析方法である。遺伝子は4つの塩基(A, G, T, C)が連なってできているが、その配列のなかで個人差のある部分があり遺伝子多型とよばれている。遺伝子多型には挿入/欠失型, VNTR, マイクロサテライト, SNPがあり、これらが遺伝子上にVNTRで5000個以上, SNPで数百万個ありとても良い指標(マーカー)とされている。マーカーの中からある間隔ごとに250から500個を選んでしらみつぶしに調べ、病気と正常のヒトで比較して病気のヒトである多型に偏って多いマーカーが見つかり、その近くにその病気の感受性遺伝子がある可能性が高いと判断される(連鎖不均衡)。あるいは罹患同胞対を多数のペアでマーカーを調べ、兄弟で一致率の高いマーカーを探す方法などもある。これらの方法は大量の遺伝子を高速で処理する必要があり、それに対処できる専門の施設で行われる。

広汎性発達障害

自閉症の特徴的な事柄を表2にまとめた。自閉症が遺伝的疾患であるとされる根拠の一つは双子研究と家族研究の結果からである。一卵性双生児の一致率は70%(36~90%)と高く、二卵性双生児の一致率は10%(0~23.5%)である。ここで一卵性双生児でもけっして100%でないということは、遺伝だけではない、つまり環境因子などが関与する可能性のあることを示唆していると思われる。兄弟の自閉症発病危険率は2~6%とされ、一般における発病率0.02~0.1%より高値であり、一般人口の有病率の約100倍に当たる。関与している遺伝子はおそらく3~15個位なのではないかと考えられている。

自閉症の中には染色体異常を伴うものがある。自閉症の染色体異常の頻度は約5~12%とされ、14と20番を除きほとんどすべての染色体について報告があり、最も頻度が高いのは15番染色体である。脆弱X症候群の6.9~

表2 自閉症の特徴

定義	DSM-IV, ICD-10 3歳以前発症
三主徴	対人関係の障害 コミュニケーションの障害 行動, 興味の限定, 常同的
遺伝学的特徴	
頻度	2-5人/10000人~1人/1000人
男女比	3~4:1
双子一致率	一卵性 36~90% 二卵性 0~23.5%
兄弟発症率	2~6%
生物学的特徴	
精神遅滞の合併	約75%
てんかんの合併	20~33%
頭が大きい	80%が平均以上 24%が2SD以上
血中セロトニン値	26~66%の症例で増加
薬物	SSRI, SDI有効例あり